ENDRA Life Sciences Reports Q1 2025 Loss but Shows Signs of Improved Cost Control

ENDRA Life Sciences Inc. (NASDAQ: NDRA) has released its financial results for the first quarter of 2025, indicating a challenging operating environment but with some signs of cost control. Below are the key points from the income statement and financial overview:

• Net Loss: The company reported a net loss of $1,036,330 for the quarter ending March 31, 2025, significantly reduced from a net loss of $2,775,700 in the same quarter last year, highlighting improved cost management.
• Operating Expenses: Total operating expenses decreased to $1,469,282 from $2,780,541 year-over-year. Key reductions were seen in:
  • Research and Development: $528,685 (a 49% decrease from $1,041,526)
  • Sales and Marketing: $68,991 (a 71% decrease from $238,660)
  • General and Administrative: $871,606 (a 42% decrease from $1,500,355)
• Cash Position: As of March 31, 2025, ENDRA reported cash and cash equivalents of $2,064,874, down from $3,229,480 at the end of the previous quarter.
• Additional Financing Required: The company continues to face liquidity issues and will require additional funding to support ongoing operations and product development as it has not yet generated any revenue from its TAEUS technology.
• Share Performance: There were 562,213 shares of common stock outstanding, with shares issued during the quarter under an At-The-Market equity offering contributing $145,803 in net proceeds.
• Warrant Liability Adjustments: The company recognized an income of $408,562 from changes in the fair value of warrant liabilities, marking a significant shift in financial performance metrics.

The company's future remains uncertain as it continues to seek pathways to profitability, with managing a cumulative deficit that exceeds $104 million. Further financing options are being evaluated, but execution remains critical amidst ongoing market pressures.

ENDRA's management has outlined a pipeline focused on expanding the application of the TAEUS technology across various clinical areas, which they believe may yet unlock substantial value for the company.
Given the financial situation, shareholders will be closely monitoring management's efforts to navigate through this phase.